Shares of TG Therapeutics Inc. (NASDAQ:TGTX) dropped 3.3% during trading on Friday . The stock traded as low as $6.05 and last traded at $6.10, with a volume of 159,867 shares changing hands. The stock had previously closed at $6.31.

TGTX has been the subject of several analyst reports. Brean Capital reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, June 7th. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research report on Thursday, April 14th. SunTrust Banks Inc. started coverage on shares of TG Therapeutics in a research report on Friday, May 27th. They issued a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research lowered shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 14th. Finally, Roth Capital reaffirmed a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research report on Thursday, June 9th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $22.33.

The firm’s market capitalization is $319.60 million. The stock has a 50-day moving average price of $6.29 and a 200-day moving average price of $8.02.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.08. On average, equities research analysts predict that TG Therapeutics Inc. will post ($1.15) earnings per share for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund boosted its stake in shares of TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned about 0.43% of TG Therapeutics worth $2,671,000 as of its most recent filing with the SEC.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.